A Multi-center Phase I/Ib Study Evaluating the Efficacy and Safety of Brentuximab Vedotin in Combination With TGR-1202, a Novel PI3K Delta Inhibitor, in Patients With Hodgkins Lymphoma

Trial Profile

A Multi-center Phase I/Ib Study Evaluating the Efficacy and Safety of Brentuximab Vedotin in Combination With TGR-1202, a Novel PI3K Delta Inhibitor, in Patients With Hodgkins Lymphoma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Dec 2017

At a glance

  • Drugs Umbralisib (Primary) ; Brentuximab vedotin
  • Indications Hodgkin's disease
  • Focus Adverse reactions
  • Sponsors TG Therapeutics Inc
  • Most Recent Events

    • 30 Nov 2017 Planned End Date changed from 1 Nov 2017 to 1 Mar 2018.
    • 30 Nov 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Feb 2018.
    • 28 Jun 2017 Planned End Date changed from 1 Jul 2017 to 1 Nov 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top